SHIRE PLC
Director/PDMR Shareholding
January 16, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
Notification of transactions by person discharging managerial responsibilities
1. Details of the person discharging managerial responsibilities
("PDMR") / person closely associated with them ("PCA")
a) Name Jeff Poulton
2. Reason for the notification
a) Position / status Chief Financial Officer - PDMR
b) Initial Initial notification
notification /
amendment
3. Details of the issuer, emission allowance participant, auction
platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Acquisition of ADSs following the automatic
transaction re-investment of dividends received, as paid to
shareholders on April 14, 2015. Mr. Poulton became
aware of the transaction on January 13, 2017.
c) Price(s) and Price(s) Volume(s)
volume(s)
$246.6702 3.904241
d) Aggregated N/A (single transaction)
information
e) Date of the April 14, 2015
transaction
f) Place of the NASDAQ Global Select Market
transaction
5. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Acquisition of ADSs following the automatic
transaction re-investment of dividends received, as paid to
shareholders on October 2, 2015. Mr. Poulton
became aware of the transaction on January 13,
2017.
c) Price(s) and Price(s) Volume(s)
volume(s)
$205.13 1.037245
d) Aggregated N/A (single transaction)
information
e) Date of the October 2, 2015
transaction
f) Place of the NASDAQ Global Select Market
transaction
6. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Acquisition of ADSs following the automatic
transaction re-investment of dividends received, as paid to
shareholders on April 12, 2016. Mr. Poulton became
aware of the transaction on January 13, 2017.
c) Price(s) and Price(s) Volume(s)
volume(s)
$180.3824 6.468702
d) Aggregated N/A (single transaction)
information
e) Date of the April 12, 2016
transaction
f) Place of the NASDAQ Global Select Market
transaction
7. Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been conducted
a) Description of Shire plc American Depositary Shares ("ADSs")
the financial
instrument, type
of instrument
Identification ISIN: US82481R1068
code
b) Nature of the Acquisition of ADSs following the automatic
transaction re-investment of dividends received, as paid to
shareholders on October 7, 2016. Mr. Poulton
became aware of the transaction on January 13,
2017.
c) Price(s) and Price(s) Volume(s)
volume(s)
$193.77 1.262528
d) Aggregated N/A (single transaction)
information
e) Date of the October 7, 2016
transaction
f) Place of the NASDAQ Global Select Market
transaction
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology,
Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com
SHIRE : Director/PDMR Shareholding
January 16, 2017 at 07:01 am EST
Share
Share
© PRNewswire - 2017
